# Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL

> **NCT04524455** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 17 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Blinatumomab
- **DRUG:** AMG 404
- **DRUG:** Dexamethasone Premedication

## Key facts

- **NCT ID:** NCT04524455
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-02
- **Primary completion:** 2023-01-24
- **Final completion:** 2023-01-24
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04524455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04524455, "Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04524455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*